COPENHAGEN (Reuters) – Novo Nordisk’s head of business development said on Friday he was confident it could launch the pill version of its experimental weight loss drug amycretin this year. decade.
“I never commit to time frames, but I would be very comfortable saying at least within this decade,” Martin Holst Lange said in an interview with Reuters.
Novo expects its two new experimental obesity drugs, cagrisema and amycretin, to have similar beneficial effects on the heart as the popular Wegovy, the group’s current flagship treatment for weight loss. .
The Danish laboratory’s share price soared on Thursday after the company announced that initial clinical trial results for its amycretin treatment showed greater effectiveness than that obtained with Wegovy.
Novo Nordisk hopes to advance the development of amycretin in its oral and injectable form simultaneously, Martin Lange said.
The group said in August that a large study showed that Wegovy also had a clear cardiovascular benefit.
The group’s head of business development also said Novo will prioritize acquisitions that can complement its portfolio of obesity and diabetes drugs rather than buying supply chain companies.
(Reporting Maggie Fick and Jacob Gronholt-Pedersen, writing by Stine Jacobsen and Louise Rasmussen; Diana Mandiá, editing by Kate Entringer)
Copyright © 2024 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
